➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Colorcon
Baxter
AstraZeneca
Mallinckrodt

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Trimetrexate glucuronate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for trimetrexate glucuronate and what is the scope of freedom to operate?

Trimetrexate glucuronate is the generic ingredient in one branded drug marketed by Medimmune Oncology and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for trimetrexate glucuronate.

Summary for trimetrexate glucuronate
Recent Clinical Trials for trimetrexate glucuronate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1
Memorial Sloan Kettering Cancer CenterPhase 1
Grupo Oncologico Cooperativo del SurPhase 2

See all trimetrexate glucuronate clinical trials

Medical Subject Heading (MeSH) Categories for trimetrexate glucuronate

US Patents and Regulatory Information for trimetrexate glucuronate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for trimetrexate glucuronate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Baxter
Johnson and Johnson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.